SARTORIUS STEDIM, DEAR TO THE CORE (SELL; -29% DOWNSIDE)
23/02/21 -" Sartorius Stedim Biotech (Sell, France) ranks as a top-notch asset, with industry-leading return metrics (FY20 ROE of 26% vs 14% for AV peers). Since we noted its phenomenal run almost two years ..."
Pages
62
Language
English
Published on
23/02/21
You may also be interested by these reports :
20/10/25
“Only when the tide goes out do you discover who’s been swimming naked.” This famous line from Warren Buffett fits well for the ...
20/10/25
Despite a significant downgrade in our estimates, our strong buy recommendation for Elekta remains unchanged. This is supported by ongoing ...
17/10/25
This quarter was strong, driven by the launch of new AI products. We were surprised by the very strong performance in North America and Europe. ...
17/10/25
Drägerwerk delivered solid preliminary Q3 2025 numbers. Revenue of €833m was up 10.1%, translating into a 370bps expansion in the EBIT margin to 6.8% ...